期刊文献+

沙立度胺、三氧化二砷联合罗盖全治疗骨髓增生异常综合征临床分析 被引量:5

Combination of thalidomide,calcitriol and andarsenic trioxide in the treatment of myelodysplastic syndrome
下载PDF
导出
摘要 目的探讨沙立度胺、三氧化二砷联合罗盖全治疗骨髓增生异常综合征的疗效和耐受性。方法设治疗组和对照组,治疗组22例:沙立度胺每晚睡前口服,初始剂量50mg/d,然后每周剂量递增50mg/d,达最大耐受量300mg/d改维持剂量75-200mg/d;罗盖全2μg/d,口服,服药3个月;三氧化二砷10mg/d,静脉滴注,每个月20次,间隔3周为1个疗程;对照组22例:予司坦唑醇、全反式维甲酸或小剂量化疗、干扰素等以及对症、支持治疗。临床疗效判断标准采用骨髓增生异常综合征国际工作组提出的新疗效标准。结果治疗组完全缓解(CR)5例(22.73%),部分缓解6例(27.27%),血液学改善(HI)8例(36.36%),无效3例,总有效率为86.36%,未发现严重不良反应,常见乏力、便秘、水肿、皮疹、肝肾轻度异常等,对症处理后好转。对照组无CR,PR2例(9.09%),HI7例(31.82%),无效13例,总有效率为40.90%,与治疗组比较差异有统计学意义(P<0.05)。结论沙立度胺、三氧化二砷联合罗盖全治疗骨髓增生异常综合征有效率高,不良反应轻微,耐受性好。 Objective To study the efficacy and tolerance of the combination of thalidomide, calcitriol and andarsenic trioxide in the treatment of myelodysplastic syndrome. Methods all patiens were randomly divided into two groups: treatment group and control group. 22 cases in treatment group: thalidomide orally every night before going to bed, the initial, The initial dose of thalidomide was 50 mg/d, then increased 50 mg/d every week until the patients reached maximal tolerance 300mg/d , the maintain dose was 100 -200 mg/d. Calcitriol was administered 2μg/d for 3 months. Arsenic trioxide was administered 10 mg/d, intravenous infusion, 20 times per month, 3 weeks interval for a course of treatment. 22 cases in control group were administered male hormone, interferon, all - trans retinoie acid or low - dose chemotherapy. Results In the treatment group, 19 (5 CR , 6 PR , 8 HI) of 22 patients had an objective response ( 86.36 % ). The side - effect was gentle inclucling fatigue, constipation, edema, tetter and abnormality of liver function and kidney function. In the control group, 9 (2 PR, 7 HI) of 22 patients had an objective response (40.90%). The response rate between two groups were significant different (P 〈 0.05). Conchtsion The combination of thalidomide, calcitriol and andarsenie trioxide thalidomide was efficient and well tolerated in the treatment of patients with myelodysplastic syndrome.
作者 王复字
出处 《海南医学》 CAS 2009年第11期42-44,共3页 Hainan Medical Journal
关键词 骨髓增生异常综合症罗盖全 沙立度胺 三氧化二砷 Myelodysplastic syndrome Caleitriol Thalidomide Arsenic trioxide
  • 相关文献

参考文献8

  • 1Mellibovsky L , Diez A , Perez Vila E. et al. Vitamin D treatment in myelodysplastic syndromes[J]. Recker, R R Br -J - Haematol,1998,100(3): 516 -520.
  • 2Wlodarski MW, Gondek LP, Nearman ZP, et al. Molecular strategies for detection and quatitation of clonal cytotoxic T - cell responses in aplastic anemia and myelodysplastie syndroms [ J ]. Blood, 2006, 108(8) : 2632 -2641.
  • 3Sekeres MA, List A. Lenalidomide ( Reviimid, CC - 5013 ) in myelodysplastic syndromes: is it any good? [ J]. Curt Hematol Rep, 2005,4(3): 182.
  • 4施均,邵宗鸿.骨髓增生异常综合征疗效评定新标准及治疗研究进展[J].中华血液学杂志,2003,24(1):47-50. 被引量:28
  • 5佟红艳,林茂芳,熊红,蔡真.三氧化二砷对人骨髓增生异常综合征细胞株MUTZ-1细胞的作用[J].浙江大学学报(医学版),2004,33(1):68-72. 被引量:30
  • 6List A. Dipergin J. Tamburini A Oppartunitieg Fir Trigen Senic triodehin the treatment of myelo dysplasfic syndroms [ J ]. Leukemia, 2003,17(8): 1499 -1507.
  • 7常保萍,张海深,王辉,王亚丽,赵变锋,孟苗.沙立度胺和环孢素A联合亚砷酸治疗骨髓增生异常综合征临床分析[J].临床血液学杂志,2007,20(5):270-271. 被引量:12
  • 8Raza A, Buonamici S, Liss KL, et al. Arsenic trioxide and thalidomide combination produces multi - lineage hematological responses in myelo dysplastlc syndromes patients, Particularly in those with high pre - therapy EVIl expression [ J ]. Leuk Res, 2004,28 ( 8 ) : 791 - 803.

二级参考文献8

  • 1魏亚明 欧英贤 路继红 等.The apoptosis of HL-60,K562 and NB4 cells induced by arsenic trioxide [J].Medical Journal of National Defending Forces in Northwest China(西北国防医学杂志),.
  • 2WLODARSKI M W, GONDEK L P, NEARMAN Z P,et al. Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome [J]. Blood, 2006,108:2632-2641.
  • 3SEKERES M A. Arsenic trioxide as a treatment for myelodysplastic syndrome[J]. Curr Hematol Rep, 2005,4:59-63.
  • 4STRUPP C, GERMING U, AIVADO M, et al. Thalidomide for the treatment of patients with myelodysplastic syndromes[J]. Leukemia, 2002,16:1-6.
  • 5SHIMAMOTO T, TOHYAMA K, OKAMOTO T, et al. Cyclosporin A therap for patients with myelodysplastic syndrome:multicenter pilot studie in Japan[J]. Leuk Res,2003,27:783-788.
  • 6LIST A, BERAN M, DIPERSIO J, et al. Opportunities for Trisenox(arsenic trioxide) in the treatment of myelodysplastic syndromes[J].Leukenia, 2003,17:1499-1507.
  • 7FADERL S, KANTARJIAN H M. Nover therapies for myelodysplastic syndromes[J]. Cancer, 2004,101:226-241.
  • 8施均,邵宗鸿.骨髓增生异常综合征疗效评定新标准及治疗研究进展[J].中华血液学杂志,2003,24(1):47-50. 被引量:28

共引文献61

同被引文献36

引证文献5

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部